--- title: "On October 10th, ASCLETIS-B spent HKD 982,400 to repurchase 100,000 shares" description: "According to the Zhitong Finance APP, ASCLETIS-B announced that on October 10, 2025, the company spent HKD 982,400 to repurchase 100,000 shares, with a repurchase price per share ranging from HKD 9.47" type: "news" locale: "en" url: "https://longbridge.com/en/news/260602142.md" published_at: "2025-10-10T10:30:04.000Z" --- # On October 10th, ASCLETIS-B spent HKD 982,400 to repurchase 100,000 shares > According to the Zhitong Finance APP, ASCLETIS-B announced that on October 10, 2025, the company spent HKD 982,400 to repurchase 100,000 shares, with a repurchase price per share ranging from HKD 9.47 to HKD 10.99 According to the Zhitong Finance APP, ASCLETIS-B (01672) announced that on October 10, 2025, the company spent HKD 982,400 to repurchase 100,000 shares, with a repurchase price of HKD 9.47-10.99 per share ### Related Stocks - [01672.HK - ASCLETIS-B](https://longbridge.com/en/quote/01672.HK.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | GIC Private Limited initiated a stake in Ascletis Pharmaby 64,128,000 shares at a price of HKD 12.18 per share | GIC Private Limited has acquired a stake in Ascletis Pharmaby purchasing 64,128,000 shares at HKD 12.18 each, totaling a | [Link](https://longbridge.com/en/news/275105288.md) | | Ascletis Pharma Boosts Share Buyback Plan to HK$500 Million | Ascletis Pharma Boosts Share Buyback Plan to HK$500 Million | [Link](https://longbridge.com/en/news/269948463.md) | | South Korea's Exports Jump 44.4% in First 10 Days of February | South Korea's Exports Jump 44.4% in First 10 Days of February | [Link](https://longbridge.com/en/news/275546525.md) | | GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets | GIC has invested approximately US$100 million in Ascletis Pharma (1672. HK) by acquiring 64,128,000 shares at an average | [Link](https://longbridge.com/en/news/275106794.md) | | Ascletis Pharma to Raise HK$835 Million via Share Placement to Fund Obesity Drug Trials | Ascletis Pharma Inc. plans to raise approximately HK$835 million through a share placement of 69,256,000 new shares at H | [Link](https://longbridge.com/en/news/274573426.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.